IMvigor011 B042843

About this trial

A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Patient Profile

This trial is for patients with High-Risk Muscle-Invasive Bladder Cancer Who are ctDNA Positive Following Cystectomy (IMvigor011)

Where’s this trial being run?

Cork University Hospital, Tallaght University Hospital, and St Vincents University Hospital

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: IMvigor011 B042843
Number: 21-38
Full Title:

A Phase III, Double-Blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy

Principal Investigator: Prof Ray McDermott
Type: Industry Sponsored
Sponsor:

ROCHE

Recruitment Started: Global: May 2021
Ireland: December 2021
Global Recruitment Target: 495
Ireland Recruitment Target: 9